We would love to hear your thoughts about our site and services, please take our survey here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Looks like they will be coming to the shareholders cap in had again very soon.
Here's the link to the presentation:
https://www.reneuron.com/wp-content/uploads/Cell-2023_November-2023.pdf
Very interesting RNS...would have probably pushed the SP up for a lot of shares but shows how unfashionable we are at the moment
Maybe there's one last twist in the tail after all. Certainly a very positive RNS, and it will be interesting to hear what comes from the conference today. Need a licencing deal signing to keep the lights on though. If they're discussing terms with partners then I presume no further director buys would be possible.
Basically, yes. Let's hope Iain can win over some hearts and minds (and financial backing) at the presentation today.
Some more inside buying would be welcome too and IMO will increase the prospect of 'shareholder support' as alluded to in said RNS.
Still a death or glory prospect. I continue to hold at this point in time, but we all know the risks here. GLA.
Everything else is noise
So what’s happened to Fosun?
Small buys, and nothing since, cash declining along with share price
Answer lower then a snakes boll cks and they don,t come much lower then that!
Clinging on to the hope from those director buys in the summer....odd thing for them to do if it's all doom and gloom but equally can't see any big numbers in terms of a buy out
Any further equity raise is completely unrealistic at this point. So they either are expecting/confident of signing licencing deals, or busy drafting the RNS that confirms the lights are being switched off and trying to find anyone who's willing to stump up for the IP. With an MCAP of £2.9m, you would hope/presume the IP is worth more than that, but only if someone actually wants it.
With no news of deals and therefore the audit's worst case scenario of cash runway to February 2024 looking ever more likely, should we assume that deals ARE in the offing?
Leaving only 3 months to fundraise via. issuing stock, with Christmas in the middle, doesn't seem prudent.
Rene is like a floating bath tub, the only trouble is somebody has thrown the plug away, just a matter of time before it sinks, all hands on deck pronto.
If there is nothing to say why say anything good news would be a first with this company you stand a better chance with premium bonds after 5 or 10 years you can get your money back, with Rene you got no chance!
They attended the conference but due to the commercially sensitive data, decided not to guest speak.
As the conference was not mentioned in an RNS, they did not deem it necessary to RNS this decision.
I did not receive any sensitive information...but I am satisfied to continue to hold at the time of print.
Not advice etc and GLA.
Nothing personal Sajy.
As a LT stock holder, I’ve watched the stock price consistently fall, I’ve also noticed that most posters were, what I would call optimists; less polite individuals may call it ramping.
Rarely has there been a dissenting voice on this board, such that any new reader may get a distorted view of prospects and may be unduly influenced as a result to buy.
I take no pleasure in my contra/balancing views having been in the main right as I too will lose my shirt! I appreciate it may be unwelcome and will leave it at that; particularly as we can’t get much lower. Your filter will therefore be unnecessary.
Surprised2 you have now been filtered as I do not have time for idiots. My post did say it was my gut feeling and that means my thoughts and not what the company have said. So get of your high horse and stop making accusations. It's idiots like you that prevent people posting, from now on I will keep my thoughts to myself.
Sajy, are you suggesting that Mr Ross and his board are hiding data that may affect the share price?
My limited understanding of UK law is that to raise funds, Rene must in return meet a number of transparency obligations: particularly making public significant information liable to impact the share price. But of course you may have an inside track to Mr Ross’ office.
Rene did attend the conference but decided against presenting the data. What could be the reason for this? Well we know that they have generated good data as stated in the recent Rns, so it's not because the data was not good. We also know that they are in discussions with third parties to sign deals. My gut feeling is that Rene have been asked not to reveal the latest data while discussions are ongoing by the third parties. I believe once a deal or deals have been signed then we will get a more comprehensive update on the data.
👍
Welcome. These chat boards, at their best, are for sharing ideas but also for helping one another when we can, IMO.
Thanks for the update LW and for keeping us in the loop.
I got an email from IR a week after my question. I only checked that account yesterday, as I had pretty much given up on getting a response. The response asked me which conference in particular!
So followed up...only to get an out of office reply! I sent the link in question (even though I had already mentioned this in the original email) and will come back when they do me. Maybe before we are all pushing up the daisies :) Should have contacted Iain direct. Hey ho.
...
the exosomes are incredibly small (and that's coming from a microscopist!) so manipulating these is difficult – it has taken years and the pharma industry will take several more to figure out various techniques and to develop instrumentation in order to eventually set industry standards. however, things are moving fast in this area.
the company has recently (see the latest rns) proved in vivo tissue targeting by exosomes produced by the company's immortalised cell lines using animal models. it's my understanding that there were three separate in vivo experimental arms carried out over the first half of 2023. two were successful whilst the third was ****ed up and had to be repeated. iain said during the agm that the repeated arm was expected to be completed at the end of september beginning of october (ie about now). i don't know any details of the experiments, but the rns was released 4th september, relatively early, so i surmise either, a) they got a wiggle on, or, b) the last arm was ****ed up again but non-essential to prove the case of targeting, or, c) they looked at a different aspect – such as loading exosomes then transporting the payload to a target tissue – which is obviously the ultimate goal...and pot of gold. this may or may not have worked, but it should in principle.
i'm relaxed about the conference no-show; i suspect the conference appearance was arranged way before the complicated in vivo experiments had concluded. i don't think it was ever advertised on reneuron's website either.
Hi Fred,
Here's my take on the current situation.
First, some historical context; Reneuron have gone from aiming to treat single disease indications (requiring long and expensive trials, in our case for stroke and RP) to a platform technology. Expensive trials can kill small biotechs...see Codiak. Chucking stem cells/pre-cursor cells loosely in to an area and hoping they magically self organise and survive, we now know, was asking too much of the little cellular blighters. They were best guesses at the time, so I can't fault them for at least trying. We have learned that putting a baby in an old people's home does not make everyone in it young again! But the science has moved forward rapidly since. Who knew 20 years ago that there was a cell-to-cell communication network that pre-dates the rise of multi-cellular organisms or that cellular clocks could be reversed?
The company's m.o. has mutated into providing shuttlebuses aka exosomes for potentially pre-existing and new therapeutic payloads to specific structures in the body. Why is this homing to certain areas so important? Many many drug trials have failed and will continue to fail due to off-target toxicity. So many Phase 1, 2, & 3 trials have flunked – think of the lost lives, billions of dollars and personal reputations ruined over the decades because of adverse events during trials. The sad thing is that many therapeutic molecules themselves were shown to be very effective at treating the diseased cells in vitro but this came at a too higher price in terms of side effects (toxicity) when put in to human volunteers. What if some of these drugs/molecules could be sent exclusively to their intended target? That's a very big win if it can be pulled off...and why I'm interested in this company.
Reneuron's history in stem cell technology is not a complete waste of time and effort, far from it, imo. They have a stem cell line that has been immortalised and can give rise to many pre-cursor cell lines which are, in turn, immortal. Without this immortalisation cellular aging issues will likely kick in and screw things up. I suspect many other stem cell candidates do not have this valuable characteristic. They have also been shown via stem cell implantation to be safe in humans (stroke and RP trials) which is obviously an important consideration for therapy credibility when considered by a regulatory body.
It's at the pre-cursor cell point at which specificity (ie. tissue targeting) comes in to play. These need to produce, amongst other things, a consistent and reliable output (of homing exosomes) in order to be considered by pharma for industrial processes and reliable treatments. That is why the immortalised cell IP is necessary and so valuable along with the tissue targeting properties. Both are essential in my view.
continued....